PTE - PolarityTE, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.8200
-0.2500 (-8.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 3.0700
Open 3.0500
Bid 2.7400 x 2900
Ask 3.8000 x 1400
Day's Range 2.7200 - 3.0700
52 Week Range 2.7200 - 18.1700
Volume 271,340
Avg. Volume 343,109
Market Cap 72.826M
Beta (3Y Monthly) 1.69
PE Ratio (TTM) N/A
EPS (TTM) -4.8420
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 2016-01-12
1y Target Est 20.43
Trade prices are not sourced from all markets
  • PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    PolarityTE, Inc. (NASDAQ:PTE): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a measure of share...

  • Business Wire

    PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NGHC), Natural Health Trends Corp. (NHTC), Omnicell, Inc. (OMCL), and PolarityTE, Inc. (PTE) on behalf of long-term stockholders.  More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of National General Holdings Corp. following a class action complaint that was filed against National General on July 25, 2019.

  • Business Wire

    SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that two abstracts demonstrating the impact of the Company’s SkinTE™ product in treating diabetes-related wounds were accepted for poster presentations at the 2019 Diabetic Foot Global Conference (DFCon), an international, interdisciplinary diabetic foot conference hosted by the Keck School of Medicine of University of Southern California in collaboration with Baylor College of Medicine and University of California San Francisco from October 17-19, 2019 in Los Angeles. Today’s announcement further signifies the Company’s momentum with its clinical research program, bringing the total SkinTE data presentations at medical conference in 2019 to 36, of which 14 were podium presentations.

  • Business Wire

    PolarityTE Selected to Present at 2019 Cell & Gene Meeting on the Mesa

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that Nikolai Sopko, MD, PhD, Chief Scientific Officer of PolarityTE, was selected to present at the annual Cell & Gene Meeting on the Mesa, which will be held from October 2-4, 2019 in Carlsbad, California. Dr. Sopko will discuss the Company’s R&D pipeline and highlight the progress made thus far with the Company’s first clinically available product, SkinTE™, an autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for use in wounds, traumas, and burns. A live video webcast of all company presentations will be available at: www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.

  • Business Wire

    PolarityTE Announces Positive Data Showing SkinTE Regenerated Full-Thickness Skin in Difficult-to-Treat Wounds

    In this retrospective multicenter cohort study, all patients treated with a single application of SkinTE regenerated full-thickness skin in wounds and achieved complete wound closure. All of the study patients had failed previous clinical standard of care or presented with complex wounds where treatments beyond skin grafting, such as a lengthy surgical procedure, would have been required. In the study, 15 patients ranging from seven to 72 years of age were treated with SkinTE after a small full-thickness skin sample was taken to create the patient-specific SkinTE product.

  • Business Wire

    PolarityTE to Attend the 2019 Cantor Global Healthcare Conference

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 in New York, NY. PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues.

  • Business Wire

    SkinTE Data Including Final Pilot Study Data Readout to be Presented at the Symposium on Advanced Wound Care Fall Meeting

    PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that four abstracts regarding the Company’s SkinTE™ product were accepted for poster presentations at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Las Vegas, which will be held from October 12-14, 2019. Notably, the final data readout from the Company’s pilot trial evaluating SkinTE for the treatment of venous stasis leg ulcers will be presented at the conference and was named the highest scoring poster abstract in the Case Series/Study Category.

  • SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
    PR Newswire

    SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting

    Podium Presentation to Highlight a Variety of SkinTE Clinical Results in Trauma, Wound, and Burn from a 15 Patient Case Series SALT LAKE CITY , Sept. 9, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: ...

  • PolarityTE Appoints Peter Cohen as Chairman of the Board
    PR Newswire

    PolarityTE Appoints Peter Cohen as Chairman of the Board

    SALT LAKE CITY, Sept. 4, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board. "It gives me great satisfaction to lead the Board during this important time at PolarityTE.  I am proud to be part of a company with such an innovative technology, which not only addresses an unmet medical need, but has the potential to become a mainstay treatment in the field of skin and tissue regeneration," said Mr. Cohen.  "There have been growing pains and unexpected challenges in the development of PolarityTE, which can occur with innovative companies, especially those that have the potential to disrupt the biotechnology industry.  I am pleased with the strides we have made to address these growing pains and challenges, and believe we have the right, disciplined approach to best position the business for growth.

  • PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference

    SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 in New York, NY. PolarityTE also announced that it will attend and meet with investors during the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York, NY. PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%
    Simply Wall St.

    Introducing PolarityTE (NASDAQ:PTE), The Stock That Tanked 80%

    PolarityTE, Inc. (NASDAQ:PTE) shareholders should be happy to see the share price up 11% in the last week. But that...

  • PolarityTE Granted Canadian Patent
    PR Newswire

    PolarityTE Granted Canadian Patent

    SALT LAKE CITY , Aug. 20, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that ...

  • PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
    PR Newswire

    PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds

    SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.

  • PolarityTE Reports Second Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports Second Calendar Quarter 2019 Results

    SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
    PR Newswire

    PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019

    SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 8, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-394-8218 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 1393700 and referencing "PolarityTE Second Quarter 2019 Earnings Call".  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Enters Oversold Territory
    Zacks

    PolarityTE Enters Oversold Territory

    PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?
    Insider Monkey

    Is PolarityTE, Inc. (PTE) A Good Stock To Buy ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?
    Simply Wall St.

    What Type Of Shareholder Owns PolarityTE, Inc.'s (NASDAQ:PTE)?

    The big shareholder groups in PolarityTE, Inc. (NASDAQ:PTE) have power over the company. Institutions will often hold...

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • Benzinga

    PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

    PolarityTE presented final results from a pilot study on the use of its SkinTE product for hard-to-treat diabetic foot ulcers, or DFUs, as a poster, which showed that 10 of the 11 patients evaluated in the study had healed DFUs within eight weeks of SkinTE application, with a mean time to heal of 29.7 days. SkinTE is an autologous, homologous human cellular and tissue-based product capable of regenerating full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. PolaityTE said the abstract will be published in the online supplement to the journal Diabetes later this year.

  • PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
    PR Newswire

    PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE

    SALT LAKE CITY, June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs). The data was presented at the American Diabetes Association's 79th Scientific Sessions conference. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.

  • Benzinga

    Ready Trader One: Events, Stocks To Watch At E3

    The 24th Electronic Entertainment Expo (E3) kicks off June 11 in Los Angeles, but the news is already flowing this weekend, with many gaming companies showcasing their biggest announcements and presentations. ...

  • PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance
    PR Newswire

    PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance

    SALT LAKE CITY, June 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) today announced that the Board of Directors has created the Office of the Chief Executive, consisting of a team of three senior executives who will focus and collaborate on commercialization, operational and financial performance, and new product development. Members of the Office of the Chief Executive include Richard Hague, Chief Operating Officer, Paul Mann, Chief Financial Officer and David Seaburg, President of Corporate Development.  Dr. Denver Lough remains the Chairman of the Board and is on indefinite administrative leave from the offices of Chief Executive Officer and Chief Research & Development Officer.

  • Analysts Recommend These 3 Falling Knives
    GuruFocus.com

    Analysts Recommend These 3 Falling Knives

    The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.